CA-SCIENTIST.COM
HealthEconomics.Com, the world’s largest digital Connected Community™ for health economics and outcomes research (HEOR), real world evidence (RWE) and market access services, today announced the findings of its 2021 Insight Survey on Value Communication in Pharma HEOR, RWE & Market Access . Value communications is one of the fastest growing – yet least well studied – areas in evidence-based healthcare.
This report, based on the most extensive survey of value communications in the life sciences to date, presents results from more than 200 professionals to better understand attitudes toward communication tools used to convey evidence and value of pharmaceuticals. Specific areas addressed in this survey fielded by HealthEconomics.Com include challenges with value communication tool development, opportunities for use, evidence demonstration, training needs, vendor sourcing and content demands by the patient, payer and provider.
“We believe our 2021 Insight Survey offers highly actionable insights for pharmaceutical manufacturers, solution providers, payers, patient groups and educational partners as we seek to develop tools that effectively communicate the evidence that demonstrates pharmaceutical value,” said Patti Peeples, RPh, PhD, President and Founder of HealthEconomics.Com. “One of the most interesting findings from our survey is the need for more solution providers who are skilled in robust yet visually compelling ways to present pharmaceutical value for various types of customers. At Scientist.com, the parent company of HealthEconomics.Com, we are seeing an upsurge in the number and types of value communications projects sourced through our enterprise two-sided marketplaces, demonstrating this increased demand from the industry.”
Unique to this report is a comparison of 2021 results with responses from a 2019 survey, as well as the presentation of findings from four key populations engaged in pharmaceutical value: value evidence developers, translators, communicators and recipients (e.g., payers and/or providers).
To learn more about the HealthEconomics.Com 2021 Value Communications Insight Survey and access the white paper, visit https://www.healtheconomics.com/value-communication-in-pharma-what-medical-communications-professionals-need-to-know
About HealthEconomics.Com
HealthEconomics.Com, a Scientist.com company, is the world’s digital Connected Community™ for health economics and outcomes research (HEOR), real world evidence (RWE) and market access services. HealthEconomics.Com provides researchers in value, evidence and access with the tools, knowledge, resources and insights they need to improve healthcare outcomes and cost-effectiveness. Visit HealthEconomics.Com to learn more.
Join HealthEconomics.Com on social media: LinkedIn , Twitter , Facebook
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis26.10.2025 01:55:00 CEST | Press release
Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) At Week 8, 70% of patients treated with Opzelura achieved a ≥75% improvement in the Eczema Area and Severity Index (EASI75) and 61.3% achieved Investigator’s Global Assessment Treatment Success (IGA-TS), co-primary endpoints of the study Based on these results, Incyte expects to file a Type-II variation application for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU) by end of year Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moder
MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem25.10.2025 10:24:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution, has entered into an exclusive worldwide multi-billion-dollar joint venture with global sports icon and undefeated UFC champion Khabib Nurmagomedov (29-0) to create a first-of-its-kind regulated ecosystem connecting global finance, sports and technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251025540563/en/ MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem The partnership will culminate in the creation of a multi-billion-dollar joint venture, MultiBank Khabib LLC, uniting two global powerhouses: MultiBank Group, a leader in regulated financial excellence, and Khabib Nurmagomedov, undefeated in the octagon and whose influence extends far beyond sport.The company will operate from MultiBank Group’s headquarters in Dubai, building
Altimetrik Completes Acquisition of SLK Software, Uniting Strengths to Unlock Value through AI-First and Digital Enablement24.10.2025 18:57:00 CEST | Press release
Altimetrik today announced the successful completion of its acquisition of SLK Software, marking a major milestone in the company’s journey to build a digital engineering powerhouse. As part of this transition, SLK Software will now operate under its new identity as “SLK, an Altimetrik company”. The integration brings together Altimetrik’s AI-first, data-led innovation capabilities with SLK’s strength in Intelligent Enterprise, Digital Operations, Intelligent Infrastructure and Automation and Quality Engineering - spanning the entire digital enablement value chain from strategy and design to engineering and managed services. Anchored in a Practitioner-Led approach, the unified organization merges deep domain expertise with modern platforms and digital operating models to deliver bite-size, outcome-focused execution that accelerates time-to-value. “I am thrilled to officially welcome the SLK team to Altimetrik, bringing together two organizations driven by purpose, innovation, and an un
Andersen Consulting samarbejder med Acronotics om at udbygge AI-styrede digitale transformationskapaciteter24.10.2025 17:55:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med Acronotics, et hurtigt voksende digitalt konsulentfirma med hovedsæde i Storbritannien og afdelinger i USA og Indien. Som specialist i AI-drevet forretningstransformation samarbejder Acronotics med Fortune 500-virksomheder om at fremskynde den digitale transformation ved hjælp af kunstig intelligens. Virksomheden har dyb ekspertise inden for produktion, bankvirksomhed og finansielle tjenester, detailhandel, hurtigt omsættelige forbrugsgoder og højteknologiske industrier med stærkt fokus på AI/ML, generativ AI og RPA-teknologi. Acronotics leverer end-to-end-tjenester, herunder design, udvikling og implementering af Agentic AI og RPA-baserede procesautomatiseringsløsninger. Ved hjælp af sin egenudviklede automatiserede digitale medarbejderstyringsplatform, Radium.ai, hjælper virksomheden sine kunder med at administrere og overvåge deres digitale arbejdsstyrke effek
LambdaTest Unveils AI-Powered Web Scanner for Scalable Visual and Accessibility Testing24.10.2025 17:00:00 CEST | Press release
New browser-based solution empowers teams to detect visual bugs and ensure accessibility compliance at scale LambdaTest, a GenAI-native quality engineering platform, today announced the launch of LambdaTest Web Scanner, an advanced browser-based tool combining Visual UI Regression Testing and WCAG-compliant Accessibility Testing. It enables teams to identify and resolve visual and accessibility issues across web applications with unparalleled speed and precision. LambdaTest Web Scanner combines key features to streamline visual and accessibility testing. It offers Visual UI Regression Testing with SmartUI technology, enabling automated scans that detect layout changes and design mismatches across browsers and screen resolutions. It also supports WCAG-compliant Accessibility Testing, identifying violations and providing recommendations for inclusivity. The tool enables cross-browser and responsive testing across multiple browsers and 200+ mobile viewports, while smart scheduling allows
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom